European journal of cancer (Oxford, England : 1990)
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Xinghao Ai, Renhua Guo, Liang Zhang, Jian Fang, Yiping Zhang, Jianhua Chen, Jun Zhao, Feng Ye, Shumei Wang, Meiqi Shi, Xinwei Zhang, Fang Zhang, Jiakui Li, Li Wang, Xuejie Guo
Published: 202610.1016/j.ejca.2026.116221
Abstract
BACKGROUND: To investigate the preclinical characterization of dirozalkib, a novel anaplastic lymphoma kinase (ALK) inhibitor, and its safety, pharmacokinetics, and preliminary antitumor activity in advanced non-small cell lung cancer (NSCLC). METHOD…
Preview only. Read the full abstract at the source